While we strive to keep our content current with the latest research and clinical guidelines, it is intended for general informational purposes only
It is a reflection of wildly different service models being compared as if they were the same thing
ARA-290 received FDA Orphan Drug Designation for this indication TRPV1-mediated pain models ARA-290 demonstrated specific inhibition of TRPV1 channel activity, relieving capsaicin-induced mechanical hypersensitivity in pre-clinical nociceptor models Complex Regional Pain Syndrome (CRPS) investigational studies have examined ARA-290 in CRPS models due to its dual anti-inflammatory and nociceptor-targeting mechanism Chronic neuropathic pain multiple studies confirm ARA-290 reduces neuroinflammation in the spinal cord by suppressing TNF-, IL-1, and other pro-inflammatory cytokines that maintain chronic pain states Neuroprotection and CNS Research: Cerebral ischaemia/stroke models Wang et al
Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study
J., Bickel, C., Torzewski, M., Hafner, G., Tiret, L., & Lackner, K
However, how AMPK regulates GLP-1 signalling pathway needs to be further investigated